Sept 29 (Reuters) - Mirum Pharmaceuticals Inc said on Wednesday that the U.S. Food and Drug Administration has approved its drug to treat itching in patients with Alagille syndrome, making it the first approved therapy for treating symptoms of the genetic disorder. (Reporting by Mrinalika Roy and Bhanvi Satija in Bengaluru; Editing by Shinjini Ganguli)